The Ultistack: AOD9604, Tesamorelin & MOTS-c — Rethinking Visceral Fat Through Synergistic Peptide Research

Introduction: Why the Conversation About AOD9604 Isn't Over

In 2007, headlines declared AOD9604 dead. The pivotal Phase IIb "OPTIONS" trial — the largest human study ever conducted on the compound — failed to meet its primary endpoint of statistically significant body mass reduction. Metabolic Pharmaceuticals halted its drug development program. Most mainstream commentary stopped there.

But for researchers who read past the press release, the story was considerably more nuanced — and far from closed.

AOD9604 is a C-terminal fragment of human growth hormone (hGH), specifically amino acids 177–191, with an additional tyrosine residue at the N-terminus for peptide stabilisation. What makes it scientifically compelling is what it doesn't do: it does not stimulate IGF-1 production, does not cause insulin resistance, and does not bind with high affinity to the GH receptor — yet it clearly shares the lipolytic properties of full hGH (Moré & Kenley, 2014). That selective profile has kept researchers interested long after the clinical program ended.

This article examines the AOD9604 literature critically, explores the context the OPTIONS trial results are rarely given, and makes the case for why combining AOD9604 with Tesamorelin and MOTS-c represents a mechanistically coherent and scientifically interesting research approach to visceral fat metabolism.

Part 1: What the Animal Data Actually Showed

Before any human trials, AOD9604 demonstrated remarkably consistent effects in animal models — specifically via intraperitoneal (IP) and subcutaneous (SQ) administration routes.

A landmark study by Heffernan et al. (2001), published in Endocrinology (PMID: 11713213), examined the effects of AOD9604 and full hGH on lipid metabolism in obese mice and beta-3 adrenoreceptor (β3-AR) knock-out mice following 14 days of chronic administration. The findings were significant:

• AOD9604 reduced body weight and body fat in obese mice comparably to full hGH
• The compound increased fat oxidation and stimulated lipolysis
• Crucially, in β3-AR knock-out mice, the lipolytic effect of AOD9604 was significantly attenuated — suggesting the β3-adrenoreceptor pathway is central to its mechanism of action
• AOD9604 achieved these effects without increasing IGF-1 levels, a key safety advantage over full hGH

Separately, rat studies demonstrated body weight reduction exceeding 50% compared to control animals, with effects concentrated in visceral and abdominal fat depots — the metabolically dangerous fat associated with cardiovascular risk and insulin resistance.

This animal data — consistently conducted via parenteral (non-oral) routes — established a strong mechanistic foundation. The compound worked, and it worked specifically through pathways relevant to visceral adiposity.

Part 2: The Phase 2 Trials — Reading Between the Lines

Six human clinical trials were conducted with AOD9604, including intravenous pilot studies, oral pilot studies, and the two large oral Phase IIb trials (Moré & Kenley, 2014).

The earlier smaller trials told an interesting story. In one 12-week randomised clinical trial, subjects receiving AOD9604 at 1 mg/day orally lost an average of 2.6 kg compared to 0.8 kg in the placebo group — a statistically meaningful difference (referenced in Misra, 2013, Current Cardiology Reviews, PMC3584306). Body mass reduction in these trials was described as modest, steady, and specifically concentrated in abdominal fat — mirroring the animal data exactly.

Then came the OPTIONS trial. The pivotal Phase IIb study enrolled over 500 obese adults across multiple sites, tested oral dosing, and incorporated an intensive diet and exercise regime as part of the protocol. The result: no statistically significant difference in body mass reduction between AOD9604 and placebo.

Two critical contextual points are almost never discussed in mainstream coverage:

1. Administration route. Every successful animal study used IP or SQ delivery. The OPTIONS trial used oral administration. AOD9604 is a peptide — a short chain of amino acids — and like all peptides, it is subject to proteolytic degradation in the gastrointestinal tract. While AOD9604 demonstrated approximately 40% oral bioavailability in pig models (Moré & Kenley, 2014), the question of how much active peptide actually reached systemic circulation in human subjects — at therapeutic concentrations — has never been fully resolved. Rapid degradation kinetics were noted in the pharmacokinetic data.

2. The lifestyle intervention confound. When a study incorporates an intensive diet and exercise programme, the resulting weight loss in the placebo group is significant. A compound producing moderate, steady fat reduction may simply be mathematically overwhelmed by the lifestyle effect — making it statistically impossible to detect a drug signal above the noise of aggressive caloric restriction and exercise. This is not evidence that the compound does not work; it is evidence that the trial design was poorly suited to detecting its effect size.

This pattern is not unique to AOD9604. It is a recognised methodological challenge in metabolic pharmacology research.

Part 3: The Route of Administration Question — Lessons from NAD+

The argument for SQ administration of AOD9604 gains further weight when examined alongside a parallel in the research peptide and nutraceutical literature: NAD+.

NAD+ (nicotinamide adenine dinucleotide) has been extensively studied in both oral and parenteral forms. Multiple studies and clinical reviews have documented that oral NAD+ demonstrates poor systemic bioavailability — largely due to GI degradation and first-pass metabolism — and does not reliably raise plasma or tissue NAD+ levels significantly (Olympia Pharmacy review of NAD oral vs injection data). Subcutaneous and intravenous administration, by contrast, bypass these barriers entirely, delivering the compound directly into systemic circulation and producing faster, more consistent and more predictable increases in blood NAD+ levels (Struth Health, 2024; TrufaMED Clinical Guide).

The biological logic here is directly applicable to AOD9604. Both are compounds with demonstrated parenteral efficacy whose oral bioavailability is compromised by GI degradation kinetics. If the principle holds for NAD+ — and the literature strongly suggests it does — the reasonable scientific hypothesis is that SQ-administered AOD9604 would produce meaningfully different systemic concentrations than oral AOD9604, potentially explaining the divergence between animal (parenteral) results and human (oral) trial outcomes.

This remains a hypothesis. A direct head-to-head human trial comparing oral versus SQ AOD9604 at matched doses has not, to our knowledge, been conducted. That gap in the literature is itself scientifically significant.

Part 4: Tesamorelin — The Only Clinically Validated Piece of the Puzzle

Unlike AOD9604, Tesamorelin carries full FDA approval — specifically for the reduction of excess visceral abdominal fat in HIV-infected patients with lipodystrophy (brand name Egrifta). This makes it the most clinically validated component of the Ultistack, and an important anchor for the stack's mechanistic rationale.

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH), the hypothalamic peptide that stimulates the pituitary to release endogenous GH. Administered subcutaneously, it produces a physiological GH pulse — raising GH levels transiently in a pattern that mimics natural pulsatile secretion — rather than the supraphysiological sustained GH exposure seen with exogenous hGH.

Multiple randomised controlled trials have demonstrated:

• Significant reductions in visceral adipose tissue (VAT) over 26–52 weeks of SQ treatment compared to placebo (Falutz et al., JAMA 2014; PMID: 25038357)
• Minimal effect on subcutaneous fat — the reduction is selective to visceral depots
• Improvements in lipid profiles including triglycerides and HDL cholesterol
• No significant impairment of glucose tolerance at therapeutic doses — a key advantage over exogenous hGH
• A more favourable safety profile than direct GH administration (ScienceDirect, 2026 review)

Tesamorelin works upstream of AOD9604 in the same pathway — stimulating endogenous GH release, which in turn activates the lipolytic cascade in adipose tissue. The combination creates complementary stimulation: Tesamorelin drives the body's own GH pulsatility, while AOD9604 directly targets the terminal lipolytic mechanism via the β3-adrenoreceptor pathway. These are additive, not redundant, mechanisms.

Part 5: MOTS-c — The Mitochondrial Dimension

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is perhaps the most novel of the three compounds and arguably the most exciting from a basic science perspective. It is a 16-amino acid peptide encoded not by the nuclear genome but by the mitochondrial genome itself — specifically the 12S rRNA region — making it a mitochondrial-derived peptide (MDP), a class of signalling molecules only discovered in the last decade.

Published research, including a pivotal 2015 study in Cell Metabolism by Lee et al. (PMID: 25738459), demonstrated that MOTS-c:

• Promotes metabolic homeostasis in mice
• Prevents age-dependent and high-fat diet-induced insulin resistance
• Prevents diet-induced adiposity in mouse models
• Activates AMP-activated protein kinase (AMPK) — the body's master metabolic regulator
• Modulates the folate cycle and de novo purine biosynthesis in skeletal muscle
• Reduces elevated adiposity and insulin resistance through skeletal muscle-targeted metabolic reprogramming

A subsequent 2019 study (PMID: 31293078) further characterised MOTS-c's metabolic effects, identifying reductions in sphingolipid metabolism, monoacylglycerol metabolism, and dicarboxylate metabolism pathways in treated mice — pathways directly linked to lipid storage and fat metabolism.

More recently, human observational data has emerged showing that circulating MOTS-c levels are dysregulated in obese adults (PMC12807633, 2025), lending additional relevance to the idea that restoring or augmenting MOTS-c signalling may have metabolic therapeutic value.

What makes MOTS-c uniquely complementary to AOD9604 and Tesamorelin is that it operates at the cellular energy production level — specifically at the mitochondria, where fatty acids are oxidised into ATP. AOD9604 and Tesamorelin work to mobilise fat from adipose stores. MOTS-c, via AMPK activation, works to ensure that mobilised fat is efficiently oxidised rather than redeposited. The mechanistic logic of the Ultistack is essentially: release the fat, then burn it.

Part 6: The Synergistic Rationale — Why These Three?

The Ultistack is not a random combination. Each compound targets a distinct but complementary node in the visceral fat metabolism pathway:

Tesamorelin drives the hormonal signal. AOD9604 executes the lipolytic action at the adipocyte. MOTS-c ensures the liberated fatty acids are oxidised efficiently at the mitochondrial level. Each acts at a different point in the cascade, reducing the risk of pathway redundancy and theoretically allowing lower doses of each individual compound to achieve meaningful combined effect — a fundamental principle of rational polypharmacy.

Part 7: The Research Gaps and Honest Limitations

Intellectual honesty requires acknowledging what is not yet known:

• There are no published human clinical trials of AOD9604 administered subcutaneously at therapeutic doses. The SQ advantage is biologically plausible and supported by precedent in other peptide research, but it is not yet directly proven in AOD9604-specific human data.
• MOTS-c human trial data remains limited. Most published data is in animal models. The human observational data is promising but not interventional.
• The Ultistack as a combination has not been studied. The synergistic rationale is mechanistically coherent but unvalidated in any published study.
• All three compounds are research-grade only. None of the uses described here are FDA or TGA approved outside of Tesamorelin's specific HIV-lipodystrophy indication.

These gaps do not invalidate the scientific interest. They define the frontier of where research needs to go.

Conclusion

The story of AOD9604 is a useful lesson in how clinical trial outcomes can obscure rather than illuminate biological truth. A compound that consistently reduced visceral fat in animal models via parenteral administration was tested orally, in the presence of intensive lifestyle intervention, and declared ineffective. That conclusion deserves scrutiny — not because negative results should be ignored, but because the conditions of the trial may have been fundamentally mismatched to the compound's pharmacokinetic profile.

The parallel with NAD+ is instructive: route of administration matters profoundly for peptides and similar compounds. The assumption that oral and SQ AOD9604 produce equivalent systemic exposure has never been rigorously tested in humans, and the pharmacokinetic data suggests it is an assumption worth questioning.

Combined with Tesamorelin's clinically validated visceral fat reduction and MOTS-c's emerging role in mitochondrial metabolic regulation, the Ultistack represents a mechanistically coherent approach to visceral fat metabolism worthy of serious research attention.

The conversation about AOD9604 isn't over. It may just be getting started.

References

1. Heffernan, M.A. et al. (2001). The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and β3-AR knock-out mice. Endocrinology. PMID: 11713213.
2. Moré, M.I. & Kenley, D. (2014). Safety and Metabolism of AOD9604, a Novel Nutraceutical Ingredient for Improved Metabolic Health. Journal of Endocrinology and Metabolism, 4(3), 64–77. doi: 10.14740/jem213w
3. Misra, M. (2013). Obesity Pharmacotherapy: Current Perspectives and Future Directions. Current Cardiology Reviews, 9(1), 33–54. PMC3584306.
4. Falutz, J. et al. (2014). Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients. JAMA. PMID: 25038357.
5. Lee, C. et al. (2015). The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance. Cell Metabolism, 21(3), 443–454. PMID: 25738459.
6. Lee, C. et al. (2019). The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and biological aging. PMID: 31293078.
7. PMC9905433 (2023). MOTS-c: A promising mitochondrial-derived peptide for metabolic disease. PMC.
8. PMC12807633 (2025). Systemic MOTS-c levels are increased in adults with obesity.